Biomarker study for atezolizumab plus bevacizumab in liver cancer
Part of Cancer, Digestive system clinical trials.
This trial looks at how well the combination of atezolizumab and bevacizumab works for people with advanced liver cancer that cannot be removed by surgery. Researchers will study blood samples to find markers that might predict how well the treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have advanced liver cancer that cannot be removed by surgery.
- You have not had any previous systemic treatment for your advanced liver cancer.
- You have at least one tumor that can be measured on a CT or MRI scan.
- You are willing to provide blood samples and attend follow-up visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how well the combination of atezolizumab and bevacizumab works for people with liver cancer that has come back or spread, based on real patient records from a hospital registry.
This trial tests combining three drugs (atezolizumab, bevacizumab, and tocilizumab) to see if they can help people with advanced liver cancer that cannot be removed with surgery. It aims to shrink tumors and improve outcomes for patients who have not had prior systemic therapy.
This trial studies how well immunotherapy drugs (atezolizumab and bevacizumab) work for people with advanced liver cancer that cannot be treated with local procedures. It looks at real-life results to see if these treatments help people live longer and feel better.
This trial tests a new combination of chemotherapy (FOLFOX) plus atezolizumab and bevacizumab for people with advanced liver cancer that has grown after having atezolizumab and bevacizumab alone. The goal is to see if adding chemo helps stop the cancer from growing further.
This trial studies whether a combination of immune therapy (atezolizumab) and a blood-vessel-targeting drug (bevacizumab) works better than a standard procedure called TACE for people with intermediate-stage liver cancer (HCC). It may help shrink tumors and help patients live longer with fewer complications.
This study is looking at how well a combination of two drugs (atezolizumab and bevacizumab) works for people with liver cancer that can't be removed by surgery. The goal is to learn how to predict the best response using lab tests and CT scans.
Hear when a new Hepatocellular Carcinoma (HCC) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.